Related Experiment Video
Updated: May 10, 2026
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
Sequencing systemic therapies in metastatic castration-resistant prostate cancer
Jane Jijun Liu1, Jingsong Zhang
1Genitourinary Oncology Program, Moffitt Cancer Center, Tampa, FL 33612, USA.
Background:
Men with prostate cancer will not die of the disease until it progresses to the metastatic castration resistant stage. At that stage, the median survival is 9 to 30 months.
Methods:
Recently approved and emerging treatments for metastatic castration-resistant prostate cancer (mCRPC) were reviewed based on their mechanisms of action, as well as sequencing and combining these treatments with existing options.
Results:
Advances in androgen deprivation therapy, immunotherapy, bone-targeted therapy, and chemotherapy have led to approvals of abiraterone acetate, sipuleucel-T, denosumab, and cabazitaxel for the treatment of mCRPC. Despite improvements in patient survival and quality of life, mCRPC remains incurable.
Conclusions:
With the emerging new therapies, this is an unprecedented time in treating mCRPC. A better understanding of their mechanisms of action, the genetic makeup of each mCRPC, and the development of new prognostic and predictive biomarkers will help determine sequencing or different combination treatments for each individual patient.
Insights
New treatments offer hope for metastatic castration-resistant prostate cancer (mCRPC), but it remains incurable. Understanding treatment mechanisms and biomarkers is key for personalized mCRPC therapy.
Area of Science:
- Oncology
- Urology
Background:
- Prostate cancer is often fatal only after progressing to the metastatic castration-resistant stage.
- Median survival for metastatic castration-resistant prostate cancer (mCRPC) is limited to 9–30 months.
Purpose of the Study:
- To review recently approved and emerging treatments for mCRPC.
- To analyze treatment mechanisms, sequencing, and combinations for mCRPC.
Main Methods:
- Literature review of approved and emerging mCRPC therapies.
- Analysis of treatment mechanisms, sequencing, and combination strategies.
Main Results:
- Advances include abiraterone acetate, sipuleucel-T, denosumab, and cabazitaxel.
- New therapies improve survival and quality of life but do not cure mCRPC.
Conclusions:
- Emerging therapies represent a significant advancement in mCRPC treatment.
- Understanding mechanisms, genetics, and biomarkers is crucial for personalized mCRPC treatment strategies.
More Related Videos
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Related Concept Videos
02:56Treatment Resistant Cancers
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...